ArticleSurgical endoscopy2026
Long-term oncologic outcomes and prognostic factors in resected stage IA pancreatic cancer: a retrospective cohort study.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStage IA pancreatic ductal adenocarcinoma (PDAC) is an early-stage disease where curative resection is feasible. While minimally invasive surgery (MIS) is increasingly used and adjuvant chemotherapy is standard for resected PDAC, their roles in stage IA patients remain unclear. This study evaluated the oncologic and perioperative outcomes of surgical approach and adjuvant chemotherapy in stage IA PDAC patients.
methodsWe retrospectively analyzed patients with histologically confirmed stage IA PDAC who underwent curative-intent pancreaticoduodenectomy (PD) or distal pancreatectomy (DP) at Severance Hospital (2005-2022). Those receiving neoadjuvant therapy or other procedures were excluded. Survival was assessed with Kaplan-Meier estimates and Cox models.
resultsAmong 102 patients, 48 (47.1%) underwent MIS and 78 (76.5%) received adjuvant chemotherapy. The mean tumor size was 1.62 cm; 49 patients had right-sided tumors and 53 had left-sided tumors. MIS was more common in the DP group than the PD group (67.9 vs. 24.5%, p < 0.001). 12 patients (11.8%) had pathologic margin involvement of the tumor in final pathology. 59 patients (57.8%) experienced complications postoperatively and 78 patients (76.5%) received adjuvant chemotherapy. The 5-year overall and disease-free survival rates were 58.2% and 48.6%, respectively. On multivariable analysis, age (HR 1.05, p = 0.027), female sex (HR 0.32, p = 0.006), and adjuvant chemotherapy (HR 0.24, p = 0.001) were independently associated with overall survival. Age and adjuvant chemotherapy were also independently associated with recurrence-free survival.
conclusionAdjuvant chemotherapy was associated with improved outcomes in stage IA PDAC overall, but did not confer an overall survival benefit in left-sided tumors, underscoring the need for larger studies to define its role in this subgroup.
Indexed as
Identifiers
41781776What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.